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ABSTRACT
Introduction Very little is known about possible 
clinical sequelae that may persist after resolution of 
acute COVID-19. A recent longitudinal cohort from Italy 
including 143 patients followed up after hospitalisation 
with COVID-19 reported that 87% had at least one 
ongoing symptom at 60- day follow- up. Early indications 
suggest that patients with COVID-19 may need even 
more psychological support than typical intensive care 
unit patients. The assessment of risk factors for longer 
term consequences requires a longitudinal study linked to 
data on pre- existing conditions and care received during 
the acute phase of illness. The primary aim of this study 
is to characterise physical and psychosocial sequelae in 
patients post- COVID-19 hospital discharge.
Methods and analysis This is an international open- 
access prospective, observational multisite study. This 
protocol is linked with the International Severe Acute 
Respiratory and emerging Infection Consortium (ISARIC) 
and the WHO’s Clinical Characterisation Protocol, which 
includes patients with suspected or confirmed COVID-19 
during hospitalisation. This protocol will follow- up a subset 
of patients with confirmed COVID-19 using standardised 
surveys to measure longer term physical and psychosocial 
sequelae. The data will be linked with the acute 
phase data. Statistical analyses will be undertaken to 
characterise groups most likely to be affected by sequelae 
of COVID-19. The open- access follow- up survey can be 
used as a data collection tool by other follow- up studies, 
to facilitate data harmonisation and to identify subsets 
of patients for further in- depth follow- up. The outcomes 
of this study will inform strategies to prevent long- term 
consequences; inform clinical management, interventional 
studies, rehabilitation and public health management to 
reduce overall morbidity; and improve long- term outcomes 
of COVID-19.
Ethics and dissemination The protocol and survey are 
open access to enable low- resourced sites to join the 
study to facilitate global standardised, longitudinal data 
collection. Ethical approval has been given by sites in 
Colombia, Ghana, Italy, Norway, Russia, the UK and South 
Africa. New sites are welcome to join this collaborative 
study at any time. Sites interested in adopting the protocol 
Strengths and limitations of this study
 ► This is an open- access protocol and data collection 
forms to facilitate standardised, multisite data col-
lection to forward knowledge into long- term conse-
quences of COVID-19.
 ► This study aims to inform strategies to prevent lon-
ger term sequalae; inform clinical management, 
rehabilitation and public health management strat-
egies to reduce morbidity; and improve outcomes.
 ► The protocol will be used to follow- up a subset of pa-
tients, already included in the existing International 
Severe Acute Respiratory and Emerging Infection 
Consortium (ISARIC) cohort of more than 95 966 
individuals hospitalised with confirmed COVID-19 
across 42 countries (as of 20 November 2020).
 ► The follow- up data will be linked with acute phase 
data already documented using the ISARIC/WHO 
standardised Core or RAPID case report forms.
 ► The data collection tool is developed to facilitate 
wide dissemination and uptake with limited re-
sources to mitigate resource limitations during the 
pandemic.
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as it is or in an adapted version are responsible for ensuring that local 
sponsorship and ethical approvals in place as appropriate. The tools are 
available on the ISARIC website ( www. isaric. org).
Protocol registration number  osf. io/ c5rw3/
Protocol version 3 August 2020
EuroQol ID 37035.
INTRODUCTION
COVID-19, caused by SARS- CoV-2 infection, can lead 
to a diverse range of clinical manifestations, ranging 
from an asymptomatic infection to an acute respiratory 
distress syndrome and multiorgan failure with high risk 
of mortality.1 It is established that SARS- CoV-2 infects the 
respiratory tract but that ensuing viral replication and 
immune response may also affect other organs, which can 
lead to a risk of heart, renal and liver injury, in addition 
to an acute systemic inflammatory response and accom-
panying circulatory shock.2–4 While most people have 
uncomplicated recoveries, some have prolonged illness 
even after recovery from the acute illness.5–7 Identifying 
longer term potential consequences and relationship 
with the acute illness is important for the management of 
patients, in particular, understanding how these interact 
and affect those already living with other conditions such 
as cardiovascular disease and cancer will be paramount.
However, very little is known about possible clinical 
sequelae that may persist after the resolution of acute 
infection. A recent longitudinal cohort of 143 patients 
followed after hospitalisation from COVID-19 in Italy 
reported that 87% had at least one ongoing symptom, 
most (55%) with three or more symptoms at 60- day 
follow- up, fatigue (53%), dyspnoea (43%), joint pain 
(27%) and chest pain (22%) being the most common. 
COVID-19 was associated with worsened quality of life 
among 44% of patients.6 Prolonged course of illness has 
also been reported among people with mild COVID-19 
who did not require hospitalisation.5 7 8
Increasing evidence also suggests that infection with 
SARS- CoV-2 can cause neurological consequences,2 
including altered mental status, comprising encephalop-
athy or encephalitis and primary psychiatric diagnoses.9 
While these symptoms arise acutely during the course 
of infection, less is known about the possible long- term 
consequences. Severely affected COVID-19 cases experi-
ence high levels of proinflammatory cytokines and acute 
respiratory dysfunction that often require assisted venti-
lation. These are known factors suggested to cause cogni-
tive decline.2 10
Post- traumatic stress disorder (PTSD) and postinten-
sive care syndrome after intensive care unit (ICU) stay has 
been well documented previously.11–13 A systematic review 
of consequences after hospitalisation or ICU stay for 
SARS- CoV and Middle East respiratory syndrome coro-
navirus found sequelae up to 6 months after discharge. 
Common consequences, besides impaired diffusing 
capacity for carbon monoxide and reduced exercise 
capacity were PTSD (39%), depression (33%) and anxiety 
(30%).14 Additionally, serial CT scans postdischarge 
after SARS- CoV showed a gradual healing of pulmonary 
injury, with pulmonary consequences lasting more than 6 
months postdischarge.15
Early indications suggest patients with COVID-19 
will need even more psychological support than typical 
post- ICU patients because of higher levels of ‘survivors’ 
guilt’ and PTSD.16 In addition, the characteristics of 
the initial cellular immune and antibody response to 
SARS- CoV-2 have not been fully defined, and it is not 
known if the immune responses generated by infection 
provides long- term protective immunity. Identifying 
multidisciplinary sequalae and complications through 
high- quality, global studies throughout the course of 
COVID-19 is important for the acute and longer term 
management of patients.4 17 The emerging data and 
anecdotal evidence of long- term recovery and persistent 
debilitating symptoms highlight the need for robust, stan-
dardised studies to assess the risk of and risk factors for 
COVID-19 sequalae.
The purpose of this study is to establish a longitudinal 
cohort of patients with COVID-19 to characterise the 
risk of long- term consequences over time in different 
populations globally.18 The primary outcome is to char-
acterise physical and psychosocial consequences in 
patients post- COVID-19 infection. Secondary outcomes 
include estimating the risk of and risk factors for post- 
COVID-19 medical sequalae, psychosocial consequences 
and long- term outcomes. The results will inform strate-
gies to prevent long- term consequences; inform clinical 
management, interventional research and direct rehabil-
itation; and inform public health management to reduce 
overall morbidity and improve outcomes of COVID-19. 
This study is open access for any sites globally to join 
the collaboration to characterise COVID-19 in different 
populations. Providing research tools that can be imple-
mented for free in low- resourced settings can increase 
equity in implementation of and inclusion in clinical 
research studies.
METHODS AND ANALYSIS
This protocol and data collection surveys have been 
developed by the ISARIC COVID-19 global follow- up 
working group and informed by a wide range of global 
stakeholders with expertise in clinical research, outbreak 
research, infectious disease, epidemiology, respira-
tory, critical care, rehabilitation, neurology, psychology, 
rheumatology, cardiology, oncology and public health 
medicine.18
Study design
This is an international prospective, observational 
multisite cohort study to assess risk of and risk factors for 
longer term physical and psychosocial consequences of 
COVID-19. The study conforms to research ethics stan-
dards and has been approved by research ethics boards 
in Colombia, Ghana, Italy, Norway and the UK and 
submitted for ethics approval in additional sites and 
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countries. All sites adopting the protocol are responsible 
for ensuring that they have local ethical approval in place.
Population and setting
This protocol builds on the ISARIC/WHO COVID-19 
Clinical Characterisation Protocol (CCP) and associated 
data collection forms already in operation, the Core and 
Rapid case report forms (CRFs).19 These CRFs were devel-
oped to standardised clinical data collection on patients 
admitted with suspected or confirmed COVID-19, with 
clinical data on more than 95 966 individuals hospitalised 
with confirmed COVID-19 infection across 42 countries 
documented in a central database (as of 20 November 
2020).18 20 These CRFs collect data on demographics, pre- 
existing comorbidities and risk factors, signs and symp-
toms experienced during the acute phase, and care and 
treatments received during hospitalisation.19
This acute phase data will be linked with the follow- up 
data to inform analysis. A subset of these patients with 
confirmed COVID-19 will be followed up over time, docu-
menting data on longer term consequences using the tier 
1 follow- up data collection surveys.18 There is no limit on 
the number of sites or countries taking part.
New clinical sites are invited to take part in this global 
collaborative effort and use these open- access tools. New 
sites can complete the Core or RAPID acute phase CRFs 
prospectively or retrospectively (figure 1). Sites adopting 
the protocol and tools for collaborative or independent 
studies are responsible for ensuring local regulatory and 
ethical approvals are in place as appropriate.
Specific inclusion and exclusion criteria for the 
follow- up cohort are as follows:
Inclusion criteria
 ► People aged 16 years and older.
 ► Laboratory or physician confirmed COVID-19.
 ► At least 1 month postdischarge from hospital or health 
centre.
 ► Person (or family member/carer for patients who 
lack capacity) consent to participate.
Inclusion of vulnerable participants
The data collection surveys and validated tools are devel-
oped for anyone who fit the inclusion criteria, including 
pregnant women, elderly and those who are immuno-
suppressed. An aligned study protocol and survey will be 
developed for following up children.
Outcomes and procedure
The follow- up protocol and survey are designed to be 
flexible in a tiered approach to be adapted depending 
on local resources and research needs. The tier 1 survey 
is designed to enable patient self- assessment to facilitate 
distribution to all patients that fit the inclusion criteria, 
using a range of methods via post, an online link for self- 
completion or via telephone or in- clinic completion. A 
combination of methods can be used to be as inclusive 
as possible and depending on site resources. The tier 1 
survey designed can be used to identify people with set 
symptoms for further in- depth in clinic analysis (tier 2). 
The tier 1 survey is open access for sites to adopt as it 
is or adapt and combine with sampling and diagnostic 
methods to support further analysis (figure 1).
Serial follow-up
The aim is to follow- up patients serially over time at regular 
intervals, for as long as there is a need and resources. The 
tier 1 initial survey will be used at the inital follow- up time-
point (at 1–3 months postdischarge). The tier 1 ongoing 
survey will be used at subsequent follow- up time points 
every 3–6 months depending on resources (figure 2). To 
faciliate combined analysis, the time frames in figure 2 are 
recommended; however, these can be adapted depending 
on local resources and needs. For sites that have capacity, 
the tier 1 form can be used to identify people for more 
in- depth in- clinic follow- up. By being designed to enable 
patient self- completion, it allows wide distribution at low 
resource need. It can also be completed via in- clinic or 
telephone assessments during check- ups or for patients 
that are still hospitalised. The module will collect data 
on demographics, hospital stay and readmissions, all- 
cause and cause- specific mortality (after the initial 
index event), specific consequences including: deep 
vein thrombosis (DVT), pulmonary embolism, recent 
febrile illness, new or persistent symptoms, quality of 
life (measured by EQ- 5D- 5L), dyspnoea (assessed using 
MRC dyspnoea scale), difficulties in functioning (UN/
Washington disability score), lifestyle and socioeco-
nomic data.18 Medical records will be used to assess if a 
person is deceased before each follow- up time point and 
documented in the database. The ISARIC collaborative 
follow- up study is registered with EuroQol. Sites that wish 
to adopt the survey for independent studies, outside of 
the ISARIC collaboration, need to register to use the 
EQ- 5D- 5L tool with EuroQol.
Substudies
The tier 1 follow- up module can be used to identify 
subsets of patients experiencing specific symptomatology 
or syndromes for further follow- up (tier 2). By using a 
tiered approach, additional specialist modules can be 
added for more complex follow- up of emerging conse-
quences in a flexible, adaptable way, of a subset of patients 
and combined with sampling and diagnostics (figures 1 
and 2).
Serial follow- up will continue beyond 12 months at 3–6 
months’ interval for up to 3 years depending on resources.
Biological samples
The tier 1 surveys can be used on its own for data collec-
tion or in combination with sampling (eg, respiratory 
samples, serum, blood, stool and urine), for immu-
nology, pathophysiology, genomics or other studies.16 
This protocol builds on the ISARIC/WHO CCP, which 
includes an adaptable research sample schedule for sites 
with resources for research sampling and analysis.19 21 
The CCP is designed to enable a harmonised, multisite 
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Figure 1 ISARIC’s adaptable COVID-19 follow- up protocol framework. CRF, case report form; CCP, Clinical Characterisation 
Protocol; DVT, deep vein thrombosis; ISARIC, International Severe Acute Respiratory and Emerging Infection Consortium; MRC, 
Medical Research Council.
 on M









pen: first published as 10.1136/bm





5Sigfrid L, et al. BMJ Open 2021;11:e043887. doi:10.1136/bmjopen-2020-043887
Open access
clinical observational research response to any severe 
or potentially severe acute infection of public health 
interest, such as COVID-19. It is a standardised protocol 
for data and biological samples to be collected rapidly in 
a globally harmonised manner.21 22 The CCP was activated 
in January 2020 to respond to COVID-19 worldwide. It 
is designed in a tiered approach and includes different 
levels of sampling schedules (acute phase and follow- up) 
that can be adapted depending on resources to be 
combined with patient data collection using the acute 
phase CRFs and the follow- up CRF.18 19
Outcomes
The primary outcome of this study is to characterise phys-
ical and psychosocial consequences in patients postacute 
COVID-19. Secondary outcomes include estimating 
the risk of and risk factors for post- COVID-19 medical 
sequalae, psychosocial consequences and post- COVID-19 
mortality.
Data collection and entry
A standardised COVID-19 follow- up survey aimed 
for global settings was developed through a series of 
virtual working group meetings and email iterations. 
The survey was piloted on patients in four settings in 
three countries, and feedback was incorporated into the 
final form. The form collects data on a wide range of 
outcomes including hospital stay and all- cause and cause- 
specific mortality (after the initial index event), new or 
persistent symptoms and complications, for example, 
DVT, pulmonary embolism, recent febrile illness, 
new, persistent symptoms, EQ- 5D- 5L, MRC dyspnoea 
scale, UN/Washington disability score, lifestyle and 
employment data. By standardising data collection, and 
providing open- access, adaptable tools focused on key 
data variables, it can optimise data quality and reduce 
the burden of research on staff while collecting the most 
relevant information to inform clinical care guidelines 
and public health.
This tier 1 follow- up survey is designed for patient 
self- assessment, via online link or paper form, or to 
be completed during in- clinic or telephone follow- up 
appointment in settings globally (figure 1).18 The CRF 
is available open access on the ISARIC website (https:// 
isaric. org/ research/ covid- 19- clinical- research- resources/ 
covid- 19- long- term- follow- up- study/) and as an electronic 
form on the ISARIC hosted REDCap database.18
Statistical analysis plan
Using the data, we will test for differences in outcomes 
across important demographic groups (age categories, 
sex, ethnicity, socioeconomic deprivation and comorbid-
ities), specific exposures (severe COVID-19, critical care 
admission and ventilation) and initial clinical sequelae 
(complications on their index admission for COVID-19). 
We plan to use this platform to conduct timely analyses 
that coincide with public health or scientific need. Given 
these requirements, new questions we have not spec-
ified within this protocol may arise. Where this occurs, 
we will develop analysis plans prior to undertaking anal-
yses, which will be made available on request. The data 
collected through the follow- up module will be linked 
with data on demographics, comorbidities, clinical 
characteristics, care and treatments collected using the 
ISARIC/WHO Core or RAPID COVID-19 CRF.19
Figure 2 Schematic overview of the follow- up data time frames. Abbreviations: CRF, case report form; ISARIC, International 
Severe Acute Respiratory and Emerging Infection Consortium.
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Fields contained within the data collection forms will 
be combined, and if an area of interest is found, the 
maximal amount of data will be used to investigate this to 
maintain sample size and power. The plan below presents 
our guiding statistical framework. Analyses will be devel-
oped concurrently with data collection using statistical 
coding script. At appropriate time intervals, scripts will 
be run to produce analyses at these timepoints over the 
course of the project.
As COVID-19 is a new disease, there are no systemati-
cally collected long- term data to base formal sample size 
calculations on. Therefore, we intend to recruit as many 
patients as possible. Through the network established 
already, this is anticipated to be very large. Therefore, as a 
minimum calculation, to perform logistic regression, we 
will use at least 10 events for each variable included in 
the regression. For a regression containing 10 explana-
tory variables, 100 events would be included within the 
model for each variable. Assuming a sequelae rate of at 
least 20%, we would need at least 500 patients that should 
be adequately achieved. As the field is rapidly evolving, 
the analyses are likely to change.
Entered data will be summarised first by using simple 
summary statistics. Categorical data will be explored 
using frequencies and percentages, with differences in 
disease severity and treatment groups tested for using 
χ2 tests or Fisher’s exact test where cell counts are under 
five. For continuous data, distribution will be established 
using histograms and density plots. Data that are normally 
distributed will be summarised using group mean aver-
ages and SD as a measure of central tendency. For non- 
parametric data, the median average will be used and 
presented alongside 25th and 75th centiles. Differences in 
normally distributed continuous data will be tested using 
Welch’s two sample t- tests for two group data and analysis 
of variance for three or more groups. Mann- Whitney U 
test will be used to compare differences across two groups 
or Kruskall- Wallis tests for three or more groups, where 
data follow a non- parametric distribution.
Outcomes will be expressed in three ways: (1) binary 
event data (for presence or absence of outcome of 
interest), (2) change over time (for continuous or ordinal 
data) or as (3) time to event data (for patients with serial 
measurements). We will calculate changes over time 
across symptom and outcome variables and use these 
changes over time to compare the effect of treatments or 
exposures on these outcomes. Time to event data will be 
captured for those who complete serial assessment forms. 
These data will be presented as Kaplan- Meier plots and 
differences tested for using log- rank tests. Competing risks 
(including death) will be accounted for using censoring.
To address the main aim of characterising the middle 
to long- term impact of COVID-19 on physical and mental 
health, we will first provide simple summaries of inci-
dence, and second, characterise which patients are at risk 
of developing these. To identify which patients are likely to 
develop persistent complications, functional impairment 
or reduced quality of life, we will use multilevel models to 
adjust for potential confounders. Level I fixed effects will 
include patient- level explanatory variables (ie, age and 
sex) and level II or III random effects will include site 
and country in the case where research questions require 
differences in country to be accounted for. Explanatory 
variables will be entered into models since clinical plau-
sibility and final model selection guided by maximisation 
of the adjusted R2 value and minimisation of the Akaike 
information criterion or Bayesian information criterion. 
For binary event data, multilevel logistic regression will 
be used, and estimates will be presented as ORs alongside 
the corresponding 95% CI. For continuous data, linear or 
generalised linear regression will be used, and estimates 
will be presented as model coefficients, with 95% CIs. 
Finally, time to event data will be presented as survival 
probability or HRs, with 95% CIs.
Statistical significance will be taken at the level of 
p<0.05 a priori. Analyses will be conducted in secure R (R 
Foundation for Statistical Computing, Vienna, Austria) 
or STATA (StataCorp LLC, Texas, USA) environments.
Data- sharing sites who wish to use ISARIC’s COVID-19 
data management and hosting support can email  ncov@ 
isaric. org to gain access to a secure data capture and 
management system. All systems are free to use and 
supported by ISARIC data management specialists. Sites 
who submit data to ISARIC will sign a Terms of Submis-
sion, enabling use of the data in collaborative analysis by 
ISARIC partners. Data entered into the ISARIC database 
are stored on the servers administered by University of 
Oxford Medical Sciences Division Information Tech-
nology Services (MSD ITS). Data are stored in two active 
primary data storage locations (Data Centres) that host 
mirrored copies of data, one located near the MSD ITS 
offices at the John Radcliffe Hospital and the second at 
the Old Road Campus Research Building (sites A and B, 
respectively, both in Headington, Oxford, UK).
Patient and public involvement
This protocol and the data collection survey has been 
informed by people living with long COVID-19. It has been 
piloted with a number of patients in different settings, 
and feedback was incorporated in the final version. This 
included suggestions on the data on symptoms collected 
and the way questions were asked as well as on the patient 
information.
Ethics and dissemination
The protocol and survey are open access to enable low- 
resourced sites to join the study to facilitate global stan-
dardised, longitudinal data collection. The tools18 are 
available in a range of languages.
Data from combined analysis will be disseminated 
through the ISARIC website and in open- access publica-
tions under group authorship. Ethical approval has been 
given by the Universidad de La Sabana’s IRB, Colombia; 
Ghana Health Service Ethics Review Committee; at the 
Comitato Etico di Brescia, Italy; South- Eastern Norway 
Regional Health Authority, Norway; the Comitato 
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Etico per la sperimentazione Clinica delle Province di 
Verona e Rovigo, Italy; the Sechenov University Ethics 
Committee, Moscow, Russian Federation; and the Univer-
sity of Witwatersrand Human Research Ethics Committee 
(Medical), Johannesburg, South Africa. In the UK, for 
day – 28 follow- up as part of the UK CCP approved by the 
South Central - Oxford C Research Ethics Committee in 
England and the Scotland A Research Ethics Committee. 
New sites are welcome to join this collaborative study at 
any time. Sites interested in adopting the protocol as it 
is or in an adapted version are responsible for ensuring 
that local sponsorship and ethical approvals are in place 
as appropriate.
Data statement
ISARIC stands by the principles of data sharing in public 
health emergencies. ISARIC supported studies will share 
quality data in a timely, valid and governed manner to 
inform public health policy and benefit patient care. 
The ISARIC hosted data platform enables rapid and 
harmonised operationalisation of data collection to a 
secure database.23 Ownership and control of the data 
entered are retained by those who enter the data. Sites 
can contribute data to combined analysis on permission. 
Technical appendix, statistical code and datasets are avail-
able from https:// isaric. org/ document/ covid- 19- data- 
management- hosting/ or by contacting:  ncov@ isaric. org. 
The data contributors will share the outcome results with 
key stakeholders to inform public health response, policy 
development and implementation. To efficiently make 
findings from this project visible and accessible to a wide 
range of stakeholders as well as to networks of individuals 
and institutions, we will use social media, including the 
ISARIC and partner institution’s websites. The consor-
tium will manage a page dedicated to this project that 
will incorporate all the tools available. The webpage 
will provide updates on the progress of the project and 
component activities and events and information on 
research.
This follow- up study is developed as an open- access 
tool to be adopted as appropriate by any site interested 
in following up patients with COVID-19 over time to 
facilitate standardised data collection globally to enable 
combined analysis. New sites globally are invited to join 
the study at any time. The outcomes of this study will 
inform strategies to prevent risk of consequences; clinical 
management, rehabilitation and public health manage-
ment needs to reduce morbidity; and improve outcomes. 
We invite hospitals and healthcare centres globally to 
collaborate and take part in the study.
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